HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal

Zacks01-08 23:41

Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2502706615?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-01-08 23:41","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2502706615","market":"us","top_or_hot":-1,"title":"HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal","media":"Zacks","content":"<div>\n<p>Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-stock-soars-skin-toxicity-154100180.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHOTH Stock Soars as Skin Toxicity Study in Cancer Patients Meets Goal\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-01-08 23:41 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/hoth-stock-soars-skin-toxicity-154100180.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is ...</p>\n\n<a href=\"https://finance.yahoo.com/news/hoth-stock-soars-skin-toxicity-154100180.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4196","symbol_name":"保健护理服务","start_time":0,"source_url":"https://finance.yahoo.com/news/hoth-stock-soars-skin-toxicity-154100180.html","article_id":"2502706615","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2502706615","pubTimestamp":1736350860,"columns":[],"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors.Per the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark. Hoth's proprietary ARIGA scale, developed in partnership with onco-dermatology experts, provides an accurate tool for measuring and evaluating improvements in skin toxicity.Additionally, 66% of patients treated withHT-001 reported reduced pain and itching scores, which significantly improved their quality of life. Importantly, all patients retained their full EGFR inhibitor dosage, ensuring the cancer treatment's complete therapeutic efficacy. This is a signific","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4196":"保健护理服务","CSTL":"Castle Biosciences, Inc.","HOTH":"Hoth Therapeutics","CTMX":"CytomX","HALO":"奥洛兹美医疗","BK4139":"生物科技","LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4007":"制药"},"translate_title":"癌症患者皮肤毒性研究达到目标，霍斯股价飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSTL":1,"CTMX":1,"HALO":1,"HOTH":1},"content_text":"Shares of Hoth Therapeutics HOTH skyrocketed 178.2% on Tuesday after the company announced positive interim safety and efficacy results from a mid-stage study of its lead candidate, HT-001, which is being developed to address skin toxicities linked to cancer patients undergoing treatment with EGFR inhibitors.\nPer the data readout from the ongoing phase IIa study, all patients treated with the candidate achieved the primary efficacy endpoint of an ARIGA score ≤1, showing significant skin toxicity improvement by the six-week mark. Hoth's proprietary ARIGA scale, developed in partnership with onco-dermatology experts, provides an accurate tool for measuring and evaluating improvements in skin toxicity.\nAdditionally, 66% of patients treated withHT-001 reported reduced pain and itching scores, which significantly improved their quality of life. Importantly, all patients retained their full EGFR inhibitor dosage, ensuring the cancer treatment's complete therapeutic efficacy. This is a significant improvement over previous reports that highlighted frequent dose reductions or treatment interruptions caused by skin-related side effects.\nIn the past three months, HOTH shares have rallied 186.6% against the industry’s 10% decline.\nImage Source: Zacks Investment Research\nBased on the encouraging interim results, Hoth believes that HT-001 has significant potential to become the new standard of care in treating severe skin toxicities associated with EGFR inhibitors, without interrupting the treatment process.\nInitial data suggest that the candidate was overall well-tolerated in the study and no treatment-related adverse events were reported.\nHOTH’s Future Development Plans for HT-001\nHoth states that this interim data supports a recent case report of rapid resolution of EGFR inhibitor-induced skin conditions using HT-001. In September 2024, the company announced positive data from the treatment of the first patient with the candidate who was experiencing papulopustular eruptions, a common and debilitating side effect of EGFR inhibitor therapy in cancer patients.\nAs the phase IIa study progresses, management expects to report more data that further validate the therapeutic benefit of HT-001 to address skin toxicities linked to this patient population. Meanwhile, Hoth continues to enroll patients in the mid-stage study.\nHoth’s Developmental Pipeline Beyond HT-001\nApart from HT-001, Hoth’s clinical pipeline consists of another investigational candidate, BioLexa, which is currently being developed in a separate early-stage study for the treatment of atopic dermatitis.\nThe company also has several other candidates in its pre-clinical portfolio, which are currently being studied for various oncology, neurology, dermatology and inflammatory indications.\n\nHoth Therapeutics, Inc. Price and Consensus\n\nHoth Therapeutics, Inc. price-consensus-chart | Hoth Therapeutics, Inc. Quote\n\nHOTH’s Zacks Rank & Stocks to Consider\nHoth currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks from the sector are Castle Biosciences CSTL, Halozyme Therapeutics HALO and CytomX Therapeutics CTMX, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.\nIn the past 30 days, 2024 estimates for Castle Biosciences’ earnings per share have remained constant at 34 cents. During the same timeframe, loss per share estimates for 2025 have remained constant at $1.84. In three months, shares of Castle Biosciences have gained 11.9%.\nCSTL’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 172.72%.\nIn the past 30 days, estimates for Halozyme Therapeutics’ 2024 earnings per share have Improved from $4.05 to $4.07. Estimates for 2025 earnings per share have increased from $4.80 to $4.81 during the same timeframe. In three months, Halozyme Therapeutics’ shares have gained 1%.\nHALO’s earnings beat estimates in three of the trailing four quarters and matched once, delivering an average surprise of 14.86%.\nIn the past 30 days, estimates for CytomX Therapeutics’ 2024 loss per share have remained constant at 5 cents. Estimates for 2025 loss per share have remained constant at 35 cents during the same timeframe. In three months, CytomX Therapeutics’ stock has lost 11.3%.\nCTMX’s earnings beat estimates in two of the trailing four quarters and missed the mark in the other two, delivering an average surprise of 115.70%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nHalozyme Therapeutics, Inc. (HALO) : Free Stock Analysis Report\nCytomX Therapeutics, Inc. (CTMX) : Free Stock Analysis Report\nHoth Therapeutics, Inc. (HOTH) : Free Stock Analysis Report\nCastle Biosciences, Inc. (CSTL) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.0","shortVersion":"4.30.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2502706615"}